Alaunos Therapeutics

Alaunos Therapeutics, Inc. (formerly: Ziopharm Oncology, Inc.) is a clinical-stage cell therapy company focused on oncology, dedicated to developing T-cell receptor (TCR) therapies based on its proprietary non-viral Sleeping Beauty gene transfer technology and TCR library, targeting shared tumor-specific hotspot mutations in key oncogenes (including KRAS, TP53, and EGFR). Committed to treating solid tumors through adoptive TCR-T cell therapy, the company has developed a proprietary, rapid, and cost-effective solution to provide tumor-specific cytotoxic T cells for a large population of cancer patients with unmet clinical needs.